Get exclusive money-saving offers and guides
Straight to your inbox
By signing up, you agree to the Finder
Privacy & Cookies Policy
and
Terms of Use, Disclaimer & Privacy Policy.
Investments
How to buy Cochlear shares
Own Cochlear shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cochlear Limited is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cochlear has a trailing 12-month revenue of around $1.3 billion. If you're looking to buy shares, check out the steps below.
How to buy shares in Cochlear
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Cochlear. Find the share by name or ticker symbol: COH. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cochlear reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Cochlear. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks
Finder Award
Our top pick for
Cheap broker fees
Finder Award
Our top pick for
Long-term investing
Finder Award
Cochlear share price
Use our graph to track the performance of COH stocks over time.Cochlear shares at a glance
Information last updated 2021-06-09.
| 52-week range | $175.7264 - $237.94 |
|---|---|
| 50-day moving average | $221.9914 |
| 200-day moving average | $209.6997 |
| Target price | $184.4 |
| PE ratio | N/A |
| Dividend yield | $1.15 (0.49%) |
| Earnings per share (TTM) | $5.294 |
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Cochlear stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cochlear price performance over time
Historical closes compared with the last close of A$228.85
| 1 week (2021-06-07) | -0.59% |
|---|---|
| 1 month (2021-05-14) | 5.74% |
| 3 months (2021-03-12) | 12.07% |
| 6 months (2020-12-14) | 16.93% |
| 1 year (2020-06-12) | 19.52% |
|---|---|
| 2 years (2019-06-14) | 12.06% |
| 3 years (2018-06-14) | 20.57% |
| 5 years (2016-06-14) | 87.58% |
Is Cochlear under- or over-valued?
Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cochlear's EBITDA
Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $266.7 million.
The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure a its profitability.
Cochlear financials
| Revenue TTM | $1.3 billion |
|---|---|
| Operating margin TTM | 17.23% |
| Gross profit TTM | $964.7 million |
| Return on assets TTM | 7.04% |
| Return on equity TTM | -13.06% |
| Profit margin | -12.22% |
| Book value | 24.974 |
| Market capitalisation | $15.5 billion |
TTM: trailing 12 months
Cochlear's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Cochlear's total ESG risk score
Total ESG risk: 24.39
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 24.39 (as at 12/31/2018) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Cochlear's environmental score
Environmental score: 3.73/100
Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Cochlear's social score
Social score: 14.34/100
Cochlear's social score of 14.34 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Cochlear's governance score
Governance score: 10.32/100
Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Cochlear's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Cochlear has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Cochlear Limited was last rated for ESG on: 2019-01-01.
| Total ESG score | 24.39 |
|---|---|
| Total ESG percentile | 44.88 |
| Environmental score | 3.73 |
| Environmental score percentile | 2 |
| Social score | 14.34 |
| Social score percentile | 2 |
| Governance score | 10.32 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Cochlear share dividends
We're not expecting Cochlear to pay a dividend over the next 12 months.
Cochlear share price volatility
Over the last 12 months, Cochlear's shares have ranged in value from as little as $175.7264 up to $237.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.372. This would suggest that Cochlear's shares are less volatile than average (for this exchange).
Cochlear overview
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
-
How to buy Cochlear shares
Steps to owning and managing Regency Centers shares.
-
How to buy The Honest Company (HNST) shares from Australia
Here's everything we know so far about The Honest Company IPO and how to buy in from Australia.
-
How to buy Cochlear shares
Steps to owning and managing Applyflow shares.
-
Cheap gas providers in SA
Compare gas plans from South Australia providers. Find a better deal and switch today.
-
Best headphones in Australia
Our expert team of reviewers pick the best headphones in Australia, with a little help from real consumer reviews.
-
Best fountain pens in Australia
From the best fountain pen for beginners to the top high-end model, these are the seven best fountain pens you can buy in Australia right now.
-
How to buy Marqeta stock from Australia when it goes public
Here's everything we know so far about the Marqeta IPO and how to buy in from Australia.
-
Best shower heads in Australia
We read hundreds of customer reviews to find the best shower heads you can buy online and in-store in Australia.
-
How to invest in the Didi Chuxing IPO from Australia
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
-
How to buy Robinhood stock from Australia
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
Ask an Expert
